Sessions
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?
Achieving Best Practice in Quality Control and Assurance
Analytics, Data and IT Tech Solutions: An Overview of Best Practices and Technology
Delivery Solutions, Improvements and Alternatives for Gene & Cell Therapy
Industry 4.0 Approaches Transforming Cell and Gene Therapy
Accelerating the Digitalisation Revolution in Cell and Gene Therapy Development
Viral Vector Development: Safe and Effective Viral Vectors for Therapeutic Success
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
26 Jan 2022
13:30
SPONSORED BY
13:30 Chairperson’s Opening
Thomas Bollenbach, Chief Technology Officer, ARMI
13:35 Metabolic and Environmental Control-Based Automation, Machine Learning and AI with the Adva X3 Platform
- Main challenges in autologous manufacturing
- Can metabolic feedback be used to reduce donor-to-donor variation?
- Improving manufacturing of cells by metabolic and environmental control coupled with machine learning
- Adaptive culturing and its implementation in the ADVA X3 automatic manufacturing platform
Ohad Karnieli, Founder & Chief Executive Officer, Adva Biotechnology
13:55 Digital Tools for Data Driven Manufacturing Technology Selection and Deployment
Nathan Moore, Associate Director, Engineering & Automation, Cell Therapies, Takeda
14:15: Considerations for Enabling Treatment & Commercial Outcomes
- Orchestration efforts leading to improved outcomes
- Commercial efforts to improve outcomes through patient support
- AI utilization
- Manufacturing to product distribution
Dale Hanna, Director of Product, AmerisourceBergen
14:35 Speaker Q&A and Panel Discussion
Including all session speakers and Joined by:
Jon Ellis, Manager, Invetech
Speakers
